Business ❯ Pharmaceuticals

Mergers and Acquisitions

Pfizer Corporate Strategy Investment Legal Disputes Biontech Takeover Bids Bidding Wars Sanofi Antitrust Issues Drug Development

Abivax’s Oral Ulcerative Colitis Pill Clears Late-Stage Trial While Cancer Cases Raise Safety Questions

The strong remission results have triggered a steep share sell-off and will force deeper safety reviews before regulators or partners move forward.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Piramal Pharma Posts ₹99 Crore Q2 Loss as CDMO Sales Slide 21%

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Pfizer Sues to Block Novo Nordisk’s Higher Metsera Bid as Board Backs Revised Offer

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

German Antitrust Watchdog Clears BioNTech’s CureVac Takeover

Pfizer Strikes U.S. Drug-Pricing Pact, Wins Exemption From 100% Import Tariff

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline